Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes.

Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes.

Weitere Versionen anzeigen (1)

Bibliographische Detailangaben
Hauptverfasser:	Coleman, R, Stevens, R, Retnakaran, R, Holman, R
Format:	Journal article
Sprache:	English
Veröffentlicht:	2007

Ähnliche Einträge

Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in Type 2 diabetes
von: Coleman, R, et al.
Veröffentlicht: (2007)

Framingham risk equations underestimate coronary heart disease risk in diabetes.
von: Stevens, R, et al.
Veröffentlicht: (2005)

Framingham equations underestimate cardiovascular risk compared with the UKPDS risk engine in people with Type 2 diabetes
von: Price, H, et al.
Veröffentlicht: (2007)

Evaluating SCORE and Framingham fatal coronary heart disease risk equations using UKPDS data
von: Coleman, R, et al.
Veröffentlicht: (2004)

Performance of the UK Prospective Diabetes Study Risk Engine and the Framingham Risk Equations in Estimating Cardiovascular Disease in the EPIC- Norfolk Cohort.
von: Simmons, R, et al.
Veröffentlicht: (2009)

Performance of the UKPDS Risk Engine and the Framingham risk equations in estimating cardiovascular disease in the EPIC-Norfolk cohort
von: Simmons, R, et al.
Veröffentlicht: (2008)

Framingham risk scores and anthropometric measurements in predicting cardiovascular risks among Malay men
von: Moy, Foong Ming, et al.
Veröffentlicht: (2008)

Machine learning provides evidence that stroke risk is not linear: The non-linear Framingham stroke risk score
von: Orfanoudaki, Agni, et al.
Veröffentlicht: (2021)

Framingham cardiovascular disease risk scores and incident frailty: the English longitudinal study of ageing.
von: Gale, C, et al.
Veröffentlicht: (2014)

A cardiovascular risk calculator for type 2 diabetes
von: Coleman, R, et al.
Veröffentlicht: (2005)

Estimating cardiovascular disease risk for individuals with Type 2 diabetes: the new UKPDS Risk Engine
von: Coleman, R, et al.
Veröffentlicht: (2007)

Estimating risk of clinically evident neuropathy in Type 2 diabetes: a UKPDS risk equation
von: Coleman, R, et al.
Veröffentlicht: (2006)

Incident nephropathy in type 2 diabetes: a UKPDS Risk Equation
von: Coleman, R, et al.
Veröffentlicht: (2005)

Comparative study of prognostic value for coronary disease risk between the U.K. Prospective diabetes study and framingham models: response to Protopsaltis et al.
von: Stevens, R, et al.
Veröffentlicht: (2004)

Validation and recalibration of the Framingham cardiovascular disease risk models in an Australian Indigenous cohort.
von: Hua, X, et al.
Veröffentlicht: (2017)

Probability of cardiovascular disease and assessing the relationship of job stress on cvd risk: a study among primary healthcare providers in Kelantan using the Framingham and Globorisk scores
von: Aziz, Wira Alfatah Ab Ayah @ Ab
Veröffentlicht: (2020)

Validation of the framingham general cardiovascular risk score in a multi-ethnic Asian population a retrospective cohort study
von: Chia, Yook Chin, et al.
Veröffentlicht: (2015)

Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study.
von: Brindle, P, et al.
Veröffentlicht: (2003)

The Framingham Study, Diabetes Mellitus and Cardiovascular Disease: Turning Back the Clock
von: Kengne, A, et al.
Veröffentlicht: (2010)

Non-HDL cholesterol is less informative than the total-to-HDL cholesterol ratio in predicting cardiovascular risk in type 2 diabetes.
von: Holman, R, et al.
Veröffentlicht: (2005)

Algorithms for assessing cardiovascular risk in women.
von: Stevens, R, et al.
Veröffentlicht: (2007)

Forecasting coronary case fatality in type 2 diabetes: a UKPDS Risk Engine equation
von: Stevens, R, et al.
Veröffentlicht: (2002)

Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74.
von: Retnakaran, R, et al.
Veröffentlicht: (2006)

Cardiovascular risk scores do not account for the effect of treatment: a review.
von: Liew, S.M., et al.
Veröffentlicht: (2011)

Cardiovascular risk scores do not account for the effect of treatment: a review.
von: Liew, S, et al.
Veröffentlicht: (2011)

Cardiovascular endocrinology: First-time heart failure increases risk of diabetes mellitus
von: Holman, R
Veröffentlicht: (2014)

Cardiovascular endocrinology: First-time heart failure increases risk of diabetes mellitus.
von: Holman, R
Veröffentlicht: (2014)

Risk of heart failure in type 2 diabetes
von: Coleman, R, et al.
Veröffentlicht: (2003)

Impact of using a non-diabetes-specific risk calculator on eligibility for statin therapy in type 2 diabetes.
von: Price, H, et al.
Veröffentlicht: (2009)

Metformin and risk of cardiovascular disease.
von: Turner, R, et al.
Veröffentlicht: (1999)

Improving glucose control and cardiovascular risk in general practice Type 2 diabetes.
von: Potts, N, et al.
Veröffentlicht: (2003)

Comparison of general cardiovascular disease risk profile with framingham coronary heart disease formula in a developing country
von: Chia, Y., et al.
Veröffentlicht: (2010)

Prediction of subclinical atherosclerosis in low Framingham risk score individuals by using the metabolic syndrome criteria and insulin sensitivity index
von: Huang, Benjamin, et al.
Veröffentlicht: (2023)

Research inefficiencies in external validation studies of the Framingham Wilson coronary heart disease risk rule: A systematic review
von: Ban, J, et al.
Veröffentlicht: (2024)

Blood Pressure and Cardiovascular Disease: Tracing the Steps From Framingham
von: Turnbull, F, et al.
Veröffentlicht: (2010)

The impact of treatment and time on cardiovascular risk scores
von: Liew, S
Veröffentlicht: (2012)

Rapid response: On validation of cardiovascular risk scores
von: Woodward, M
Veröffentlicht: (2016)

Validity of the Framingham point scores in the elderly: results from the Rotterdam study.
von: Koller, M, et al.
Veröffentlicht: (2007)

Are the cardiovascular risk reductions seen with empagliflozin in the EMPA-REG OUTCOME trial explained by conventional cardiovascular risk factors?
von: Coleman, R, et al.
Veröffentlicht: (2017)

Barriers to cardiovascular disease risk scoring and primary prevention in Europe.
von: Hobbs, R, et al.
Veröffentlicht: (2010)